Debates continue in the government’s quest to push down the cost of prescription drugs as two new treatments, one for postpartum depression and another for depression hit the market with high price tags. Others are tackling “surprise” medical bills, but the ramifications are problematic. These topics and more in this week’s Innovation Partners BioBlog. It ...

Nationwide, Congress, insurers, and others continue to wrestle with the costs of healthcare. What is good for some consumers may be bad for others, and a bipartisan coalition is asking the Trump Administration to consider this while they work on legislation regarding drug pricing. Other actions are trying to reduce ‘surprise’ bills from providers, while ...

In this week's Innovation Partners BioBlog, we look at how United Health and its pharmacy benefits management arm, OptumRX, are looking to pass rebates to new employer customers to deflect criticism from many fronts. Scott Gottlieb, the FDA Chief, announced he is stepping down, possibly as early as April. Hospitals are struggling to get paid ...

That’s the subject of this week’s Innovation Partners BioBlog. A bipartisan group wishes to delay the health insurance tax by two years. Blue Cross Blue Shield wishes to see ObamaCare subsidies expanded. Meanwhile, consumers aren’t seeing value in value-based care, a finding that surprised researchers. This and more from the world of healthcare in this ...

Seven CEOs from the world’s largest pharmaceutical companies met with lawmakers on Capitol Hill for what some are calling a potential turning point in the public perception of the industry. The meetings focus on the continued outcry against the rising cost of drugs. For instance, insulin, which has not changed much since its launch over ...

NCCN Academy for Excellence & Leadership in Oncology Click image for more information School of Pharmaceutical & Biotech Business3.20.19 Orlando, FLLearn about models for successful collaboration in practice management and Health Information Technology Payment, efficacy and outcomes are center stage in this week’s Innovation Partners BioBlog. First, we look at costs: the cost ...

This week’s Innovation Partners BioBlog explores the ideas, thinking, and policies that shape the debate around lowering the cost of healthcare and drugs. A new study finds that Medicare and Medicaid are better at keeping spending per beneficiary low. The Trump Administration may be putting more generic drugs through the FDA process faster, but are ...

This week’s Innovation Partners BioBlog reports on the accelerated timeline for Anthem’s new PBM as well as GlaxoSmithKline’s move to acquire Merck KGaA cancer immunotherapy. ASCO names treatments for rare cancer as the “Advance of the Year,” and the University of Pittsburgh School of Medicine’s discovery may repurpose an anti-rejection drug as a cancer treatment. ...

This week’s Innovation Partners BioBlog looks at changes to California’s Medicaid program that may shake up the current Medi-Cal system. Debate continues on step therapy in Medicare, Part B and Medicare unveiled a new app intended to help people determine what is covered. Oncologists and others require more information and education about oncology biosimilars, a ...

In this week’s Innovation Partners BioBlog, we look at a new payment model unveiled by CMS as well as new deals between Walmart and CVS. A doctor examines the pros and cons of dispensing oral oncolytics through clinics rather than specialty pharmacies. One hospital is waiving payments until the government shutdown ends to bring relief ...